Proprietary Formulations and Drug Candidates
Pharmaceutical Candidates Designed to Address 5 Major Clinical Indications
Pipeline of Proprietary Drug Candidates
Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna has developed a pipeline of indication-specific drug candidates that are in various stages of clinical development, registration, and commercialization
These cannabinoid-based drug candidates are designed to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders.
Trunerox™ – 10% CBD (100 mg/ml Cannabidiol)
Pharmaceutical preparation under GMP standards with proprietary formulation with enhanced absorption
Marketing authorization is expected during early 2023 in Brazil and other South American markets. Trunerox will be available with accessible pricing, utilizing the company’s vertical integration.